← SEC 公告列表 | MBRX SEC 公告 | Moleculin Biotech Inc.（MBRX）

業績公告 即時報告 8-K 2026-05-15

Moleculin Biotech提交8-K公佈首季業績及藥物管線進展

於 SEC 網站開啟原文

AI 繁中摘要

Moleculin Biotech（股票代碼：MBRX）於2026年5月15日向美國證監會提交8-K申報文件，公佈截至2026年3月31日的第一季度財務業績及近期營運亮點。📄 是次申報屬強制性即時報告（8-K），主要項目為Item 2.02（營運與財務狀況結果）。公司同時發佈了新聞稿（作為附件99.1），詳細載列季度收入、研發開支、現金狀況等關鍵數字，以及藥物管線進展（如Annamycin及WP1122等臨床試驗更新）。由於新聞稿為獨立文件，具體財務數據及管理層展望需參閱附件內容。 對投資者而言，8-K的提交意味著公司已公開最新季度表現，可能觸發股價波動。建議投資者仔細閱讀所附新聞稿，以掌握收入趨勢、現金消耗率及臨床里程碑等影響估值的重要因素。⚠️ 生物科技股對臨床數據尤其敏感，任何正面或負面結果均可能帶來顯著價格變動。
展開英文正文 
mbrx20260514_8k.htm

 

false
0001659617

0001659617

2026-05-15
2026-05-15

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 15, 2026

 

 

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 
 
 Delaware

 
 
 001-37758

 
 
 47-4671997

 
 

 
 
 (State or Other Jurisdiction of Incorporation

 or Organization)

 
 
 (Commission File No.)

 
 
 (I.R.S. Employer Identification No.)

 
 

 

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

 

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 
 
 ☐

 
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
 

 
 
 ☐

 
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
 

 
 
 ☐

 
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 

 
 
 ☐

 
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

 
 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 
 Title of each class

 
 
 Trading Symbol (s)

 
 
 Name of each exchange on which registered

 
 

 
 
 Common Stock, par value $.001 per share

 
 
 MBRX

 
 
 The NASDAQ Stock Market LLC

 
 

 

 

 

 

 
 
 Item 2.02

 
 
 Results of Operations and Financial Condition.

 
 

 

On May 15, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

 

 
 
 Item 9.01 

 
 
 Financial Statements and Exhibits.

 
 

 

(d)     Exhibits.

 

 
 
 Exhibit

 No.

 
 
 Description

 
 

 
  
 
  

 
 

 
 
 99.1

 
 
 Press Release dated May 15, 2026

 
 

 
  
 
  

 
 

 
 
 104

 
 
 Cover page Interactive Data File (embedded within the Inline XBRL document)

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
  
 
 MOLECULIN BIOTECH, INC.

 
 

 
  
  
 

 
  
  
 

 
  
 
 Date:  May 15, 2026

 
 

 
  
  
 

 
  
 
 By:  /s/ Jonathan P. Foster 

 
 

 
  
 
 Jonathan P. Foster

 
 

 
  
 
 Chief Financial Officer